Could nanoparticle systems have a role in the treatment of cerebral gliomas?

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 6, 2011, Pages 744-752

  Caruso, Gerardo ^a   Caffo, Mariella ^a   Alafaci, Concetta ^a   Raudino, Giuseppe ^a   Cafarella, Daniele ^a   Lucerna, Sebastiano ^a   Salpietro, Francesco M ^a   Tomasello, Francesco ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Blood brain barrier; Glioma; Gliomagenesis; Nanoparticle systems

Indexed keywords

BLOOD-BRAIN BARRIER; BRAIN DELIVERY; BRAIN TUMORS; CEREBRAL GLIOMAS; CLINICAL PROBLEMS; CONTRAST AGENT; DELIVERY VECTOR; FUNCTIONAL ORGANIZATION; GLIOMA; GLIOMAGENESIS; HIGH RATE; MULTIFUNCTIONALITY; NANO-METER SCALE; NANOPARTICLE SYSTEMS; NON-SPECIFICITY; ONE DIMENSION; POTENTIAL VECTORS;

BLOOD; BRAIN; TUMORS;

NANOPARTICLES;

CARBON NANOTUBE; DENDRIMER; DOXORUBICIN; GOLD NANOPARTICLE; LIPOSOME; MAGNETIC NANOPARTICLE; NANOPARTICLE; PACLITAXEL; QUANTUM DOT; SOLID LIPID NANOPARTICLE; TOPOTECAN;

BLADDER CANCER; BLOOD BRAIN BARRIER; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; DRUG TARGETING; GLIOBLASTOMA; GLIOMA; HUMAN; NONHUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; NANOPARTICLES;

EID: 82255186524     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.02.008     Document Type: Review

References (72)

1. Kleihues P., Louis D.N., Scheithauer B.W., Rorke L.B., Reifenberger G., Burger P.C., et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002, 61:215-229.
2. Laws E.R., Parney I.F., Huang W., Anderson F., Morris A.M., Asher A., et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project. J Neurosurg 2003, 99:467-473.
3. Stupp R., Hegi M.E., van den Bent M.J., Mason W.P., Weller M., Mirimanoff R.O., et al. Changing paradigms: an update on the multidisciplinary management of malignant glioma. Oncologist 2006, 11:165-180.
4. Wen P.Y., Yung W.K., Lamborn K.R., Dahia P.L., Wang Y., Peng B., et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006, 12:4899-4907.
5. Burger P.C., Dubois P.J., Schold S.C., Smith K.R., Odom G.L., Crafts D.C., et al. Computerized tomographic and pathological studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 1983, 58:159-169.
6. Ruben J.D., Dally M., Bailey M., Smith R., Mclean C.A., Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006, 65:499-508.
7. Dougherty T.J. An update on photodynamic therapy applications. J Clin Laser Med Surg 2002, 20:3-7.
8. Zhang L., Gu F.X., Chan J.M., Wang A.Z., Langer R.S., Farokhzad O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008, 83:761-769.
9. Tiwari S.B., Amiji M.M. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 2006, 3:219-232.
10. Pardridge W.M. Why is the global CNS pharmaceutical market so underpenetrated?. Drug Discov Today 2002, 7:5-7.
11. Garcia-Garcia E., Andrieux K., Gil S., Couvreur P. Colloidal carriers and blood brain barrier (BBB) translocation: a way to deliver drugs to the brain?. Int J Pharm 2005, 298:274-292.
12. Lesniak M.S., Upadhyay U., Goodwin R., Tyler B., Brem H. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 2005, 25:3825-3831.
13. Misra A., Ganesh S., Shahiwala A., Shah S.P. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 2003, 6:252-273.
14. Béduneau A., Saulnier P., Benoit J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28:4947-4967.
15. Michotte A., Neyns B., Chaskis C., Sadones J., In 't Veld P. Neuropathological and molecular aspects of low-grade and high-grade gliomas. Acta Neurol Belg 2004, 104:148-153.
16. Rich J.N., Hans C., Jones B., Iversen E.S., McLendon R.E., Rasheed B.K., et al. Gene expression profiling an genetic markers in glioblastoma survival. Cancer Res 2005, 65:4051-4058.
17. Holland E.C. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001, 2:120-129.
18. Stegh A.H., Kim H., Bachoo R.M., Forloney K.L., Zhang J., Schulze H., et al. BcI2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 2007, 21:98-111.
19. Kondo M., Asai T., Katanasaka Y., Sadzuka Y., Tsukada H., Ogino K., et al. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer 2004, 108:301-306.
20. Jiang A., Lehti K., Wang X., Weiss S.J., Keski-Oja J., Pei D. Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc Natl Acad Sci U S A 2001, 98:13693-13698.
21. Sato H., Takino T., Miyamori H. Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis. Cancer Sci 2005, 96:212-217.
22. Deryugina E.I., Bourdon M.A., Jungwirth K., Smith J.W., Strongin A.Y. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer 2006, 29:351-364.
23. Hatakeyama H., Akita H., Ishida E., Hashimoto K., Kobayashi H., Aoki T., et al. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm 2007, 342:194-200.
24. Pinkstaff K., Detterich J., Lynch J., Gall C. Integrin subunit gene expression is regionally differentiated in adult brain. J Neurosci 1999, 19:1541-1556.
25. Nisato R.E., Tille J.C., Jonczyk A., Goodman S.I., Pepper M.S. Alphaν beta 3 and alphaν beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003, 6:105-119.
26. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296:2404-2407.
27. Bello L., Giussani C., Carrabba G., Pluderi M., Costa F., Bikfalvi A. Angiogenesis and invasion in gliomas. Cancer Treat Res 2004, 117:263-284.
28. Webb C.P., Vande Woude G.F. Genes that regulate metastasis and angiogenesis. J Neurooncol 2000, 50:71-87.
29. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
30. Caffo M., Germanò A., Caruso G., Meli F., Galatioto S., Sciacca M.P., et al. An immunohistochemical study of extracellular matrix proteins laminin, fibronectin and type IV collagen in paediatric glioblastoma multiforme. Acta Neurochir (Wien) 2004, 146:1113-1118.
31. Kremer C., Breier G., Risau W., Plate K.H. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res 1997, 57:3852-3859.
32. Plate K.H., Breier G., Weich H.A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845-848.
33. Backer M.V., Gaynutdinov T.I., Patel V., Bandyopadhyaya A.K., Thirumamagal B.T., Tjarks W., et al. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther 2005, 4:1423-1429.
34. Chen J., Wu H., Han D., Xie C. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Lett 2006, 231:169-175.
35. Li L., Watchow C.A., Danthi S.N., Shen Z., Dechene M., Pease J., et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys 2004, 58:1215-1227.
36. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160.
37. Lee C.C., MacKay J.A., Frechet J.M., Szoka F.C. Designing dendrimers for biological applications. Nat Biotechnol 2005, 23:1517-1526.
38. Huang X., Jain P.K., El-Sayed I.H., El-Sayed M.A. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine (Lond.). 2007, 2:681-693.
39. Loo C., Lowery A., Halas N., West J., Drezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett 2005, 5:709-711.
40. Kim K.Y. Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomed Nanotechnol Biol Med 2007, 3:103-110.
41. Zhang Z., Yang X., Zhang Y., Zeng B., Wang S., Zhu T., et al. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res 2006, 12:4933-4939.
42. Lu A.H., Salabas E.L., Schuth F. Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew Chem Int Edn Engl 2007, 46:1222-1244.
43. Pison U., Welte T., Giersig M., Groneberg D.A. Nanomedicine for respiratory diseases. Eur J Pharmacol 2006, 533:341-350.
44. McNeil S.E. Nanotechnology for the biologist. J Leukoc Biol 2005, 78:1-10.
45. Montet X., Funovics M., Montet-Abou K., Weissleder R., Josephson L. Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem 2006, 49:6087-6093.
46. Van Vlerken L.E., Duan Z., Seiden M.V., Amiji M.M. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res 2007, 67:4843-4850.
47. Marquis B.J., Love S.A., Braun K.L., Haynes C.L. Analytical methods to assess nanoparticle toxicity. Analyst 2009, 134:425-439.
48. Nel A., Xia T., Madler L., Li N. Toxic potential of materials at the nanolevel. Science 2006, 311:622-627.
49. De Jong W.H., Borm P.J.A. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed 2008, 3:133-149.
50. Koo Y., Reddy G.R., Bhojani M., Schneider R., Philbert M.A., Rehemtulla A., et al. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev 2006, 58:1556-1577.
51. Moffat B.A., Reddy G.R., McConville P., Hall D.E., Chenevert T.L., Kopelman R.R., et al. A novel polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging 2003, 324-332.
52. Kircher M.F., Mahmood U., King R.S., Weissleder R., Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003, 63:8122-8125.
53. Veiseh O., Sun C., Gunn J., Kohler N., Gabikian P., Lee D., et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 2005, 5:1003-1008.
54. Sun C., Veiseh O., Gunn J., Fang C., Hansen S., Lee D., et al. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 2008, 4:372-379.
55. Krasovitski B., Kislev H., Kimmel E. Modeling phototermal and acoustical induced microbubble generation and growth. Ultrasonics 2007, 47:90-101.
56. Weizmann Y., Patolsky F., Lioubashevski O., Willner I. Magneto-mechanical detection of nucleic acids and telomerase activity in cancer cells. J Am Chem Soc 2004, 126:1073-1080.
57. Xing Y., Xia Z., Rao J. Semiconductor quantum dots for biosensing and in vivo imaging. IEEE Trans Neurobiosci 2009, 1:4-13.
58. Orringer D.A., Koo Y., Kopelman R., Sagher O. Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy. Clin Pharmacol Ther 2009, 85:531-534.
59. Reddy G.R., Bhojani M.S., McConville P., Moody J., Moffat B.A., Hall D.E., et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006, 12:6677-6686.
60. Bernardi R.J., Lowery A.R., Thompson P.A., Blaney S.M., West J.L. Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. J Neurooncol 2008, 86:165-172.
61. Wang C., Huang Y., Peng C. Photothermal ablation of stem-cell like glioblastoma using carbon nanotubes functionalized with anti-CD133. ICBME 2008. Proceedings 2009, 23:888-891.
62. Wilson D.R. Viral-mediated gene transfer for cancer treatment. Curr Pharm Biotechnol 2002, 151-164.
63. Majoros I.J., Myc A., Thomas T., Mehta C.B., Baker J.R. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 2006, 7:572-579.
64. Chien A.J., Illi J.A., Ko A.H., Korn W.M., Fong L., Chen L.M., et al. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Pacitaxlel for advanced solid malignancies. Clin Cancer Res 2009, 15:5569-5575.
65. Steiniger S.C.J., Kreuter J., Khalansky A.S., Skidan I.N., Bobruskin A.I., Smirnova Z.S., et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 2004, 109:759-767.
66. Schneider T., Becker A., Ringe K., Reinhold A., Firsching R., Sabel B.A. Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol 2008, 195:21-27.
67. Madhankumar A.B., Slage-Webb B., Mintz A., Sheehan J.M., Connor J.R. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol Cancer Ther 2006, 5:3162-3169.
68. Chertok B., David A.E., Huang Y., Yang V.C. Glioma selectively of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J Control Release 2007, 122:315-323.
69. Ljubimova J.Y., Fujita M., Khazenzon N.M., Lee B.S., Wachsmann-Hogiu S., Farkas D.L., et al. Nanoconjugate based on polymalic acid for tumor targeting. Chem Biol Interact 2008, 171:195-203.
70. Bernardi A., Braganhol E., Jager E., Figueiro F., Edelweiss M.I., Pohlmann A.R., et al. Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett 2009, 281:53-63.
71. Lu W., Sun Q., Wan J., She Z., Jiang X. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res 2006, 66:11878-11886.
72. Caruso G., Caffo M., Raudino G., Alafaci C., Salpietro F.M., Tomasello F. Antisense oligonucleotides as an innovative therapeutic strategy in the treatment of high-grade gliomas. Rec Patents CNS Drug Discov 2010, 5:53-69.